Literature DB >> 26264182

Mesenchymal stromal cells are genetically stable under a hostile in vivo-like scenario as revealed by in vitro micronucleus test.

Shikha Sharma1, Ramesh Bhonde2.   

Abstract

BACKGROUND AIMS: Mesenchymal stromal cells (MSCs) have elicited a great hope in the field of regenerative medicine because of their high therapeutic potential in treating several disorders. Therefore, from the clinical point of view, it is essential to understand genetic stability and survival of MSCs under different in vivo scenarios. Recently, we have reported nuclear blebs and micronuclei as a marker of genetic instability in MSCs.
METHODS: In our present study, we exposed umbilical cord MSCs and placenta-derived MSCs to diverse conditions simulating an in vivo scenario and studied their genetic stability by use of an in vitro micronucleus test.
RESULTS: We observed that a sudden decrease in oxygen concentration led to an increase in the number of nuclear blebs and decrease in proliferation rate without inducing senescence. Moreover, we also observed that 2.5% hypoxia exerted a markedly different pattern of regulation of various cell cycle checkpoint genes such as hypoxia-inducible factor-1α (HIF-1α), ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3 related (ATR), p53, p21, p27 and p21 than did 5% hypoxia. It is interesting to note that the MSCs were genetically stable under hyperglycemic and ischemic conditions and underwent quiescence on serum starvation accompanied by hypoxia. We also tested the genotoxicity of conditioned media derived from adverse conditions and observed that it did not result in genetic instability.
CONCLUSIONS: Our data demonstrate for the first time that umbilical MSCs and placenta-derived MSCs are genetically stable under hostile in vivo situations, indicating their suitability for therapeutic purposes.
Copyright © 2015 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nuclear blebs; high glucoose; hypoxia; ischemia; mesenchymal stem cells; micronuclei

Mesh:

Substances:

Year:  2015        PMID: 26264182     DOI: 10.1016/j.jcyt.2015.07.004

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  5 in total

Review 1.  Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms.

Authors:  Connor Stonesifer; Sydney Corey; Shaila Ghanekar; Zachary Diamandis; Sandra A Acosta; Cesar V Borlongan
Journal:  Prog Neurobiol       Date:  2017-07-23       Impact factor: 11.685

2.  Evaluation of Three Devices for the Isolation of the Stromal Vascular Fraction from Adipose Tissue and for ASC Culture: A Comparative Study.

Authors:  Jonathan Rodriguez; Anne-Sophie Pratta; Nacira Abbassi; Hugo Fabre; Fanny Rodriguez; Cyrille Debard; Jacqueline Adobati; Fabien Boucher; Frédéric Mallein-Gerin; Céline Auxenfans; Odile Damour; Ali Mojallal
Journal:  Stem Cells Int       Date:  2017-02-22       Impact factor: 5.443

3.  Evaluating Wharton's Jelly-Derived Mesenchymal Stem Cell's Survival, Migration, and Expression of Wound Repair Markers under Conditions of Ischemia-Like Stress.

Authors:  Iris Himal; Umesh Goyal; Malancha Ta
Journal:  Stem Cells Int       Date:  2017-02-07       Impact factor: 5.443

Review 4.  Role of Hyperglycemia in the Senescence of Mesenchymal Stem Cells.

Authors:  Min Yin; Yan Zhang; Haibo Yu; Xia Li
Journal:  Front Cell Dev Biol       Date:  2021-04-15

5.  Mathematical modelling of interacting mechanisms for hypoxia mediated cell cycle commitment for mesenchymal stromal cells.

Authors:  Bo Zhang; Hua Ye; Aidong Yang
Journal:  BMC Syst Biol       Date:  2018-04-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.